

# Imatinib Adherence Testing

ARUP now offers a **therapeutic drug monitoring (TDM)** test for chronic myelogenous leukemia (**CML**) and gastrointestinal stromal tumor (**GIST**) patients being treated with the tyrosine kinase inhibitor (**TKI**) imatinib.

## Why Is This Testing Important?

Imatinib is a first-line treatment for CML and GIST and is most effective when trough levels (C<sub>min</sub>) are maintained above a predetermined therapeutic level.

- CML: 1000 ng/mL target
- GIST: 1100 ng/mL target


Imatinib, when dosed according to TDM, yields similar MMR as second generation TKIs.

## Laboratory Testing at ARUP

test code	test name
-----------	-----------

<b>3000539</b>	<b>Imatinib</b>
----------------	-----------------

- Ordering Recommendation: Optimize drug therapy and monitor patient adherence.
- Fast turnaround time (1–5 days).



For additional information and references, visit:  
[www.aruplab.com/topics/imatinib](http://www.aruplab.com/topics/imatinib)





[www.aruplab.com](http://www.aruplab.com)

**ARUP LABORATORIES**

500 Chipeta Way  
Salt Lake City, UT 84108-1221

Phone: (800) 522-2787

Fax: (801) 583-2712

keyword: IMATINIB

*A nonprofit enterprise of the University of  
Utah and its Department of Pathology*

© 2018 ARUP Laboratories  
BD-CS-068, Rev 0, June 2018



[www.aruplab.com/  
topics/imatinib](http://www.aruplab.com/topics/imatinib)